Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 4, Issue 4, Pages 215-220
http://dx.doi.org/10.1155/S1064744996000415

Azithromycin (Zithromax®)

Hilltop Research Centers, 6079 N. Fresno #101, Fresno 93710, CA, USA

Received 2 July 1996; Accepted 16 July 1996

Copyright © 1996 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Azithromycin (Zithromax®, Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive penetration into intracellular and interstitial tissue compartments, accompanied by prolonged tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms. Azithromycin provides short-duration, high-compliance, cost-effective regimens that should improve outcomes.